- Featured Product
- KD/KO Validated
FRS2 Polyclonal antibody
FRS2 Polyclonal Antibody for WB, IHC, IF/ICC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat and More (1)
Applications
WB, IHC, IF/ICC, ELISA
Conjugate
Unconjugated
Cat no : 11503-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | HeLa cells, SH-SY5Y cells, human brain tissue, NIH/3T3 cells, PC-3 cells |
| Positive IHC detected in | human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 9 publications below |
| IHC | See 2 publications below |
Product Information
11503-1-AP targets FRS2 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, monkey |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | FRS2 fusion protein Ag2052 相同性解析による交差性が予測される生物種 |
| Full Name | fibroblast growth factor receptor substrate 2 |
| Calculated molecular weight | 60 kDa |
| Observed molecular weight | 68 kDa |
| GenBank accession number | BC021562 |
| Gene symbol | FRS2 |
| Gene ID (NCBI) | 10818 |
| RRID | AB_2262942 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Fibroblast growth factor (FGF) receptor substrate 2 (FRS2) has an alternative name as SNT-1, it is an adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. FGF receptor substrates (FRS2 and FRS3) are key adaptor proteins that mediate FGF-FGFR signalling in benign as well as malignant tissue. FRS2 is a 508 amino-acid protein,which is phosphorylated on tyrosine residues. The molecular weight of non-phosphorylated FRS2 is 57-68 kDa, but phosphorylated FRS2 is 80-90 kDa. Phosphorylation of FRS2 is associated with activation of a number of MAP kinases. Allele-specific regulation of FGFR2 mRNA expression with a mildly increased breast cancer risk has been reported.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for FRS2 antibody 11503-1-AP | Download protocol |
| IHC protocol for FRS2 antibody 11503-1-AP | Download protocol |
| IF protocol for FRS2 antibody 11503-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cancer Res Transcriptomics and transposon mutagenesis identify multiple mechanisms of resistance to the FGFR inhibitor AZD4547. | ||
Cancer Res Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. | ||
J Med Chem Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. | ||
Cells FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist | ||
Breast Cancer Res FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. | ||
Genes Chromosomes Cancer High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. |
